I f prostate cancer has spread to other areas of your body, your doctor may recommend androgen deprivation therapy (ADT), which halts the production of androgen hormones, especially testosterone.

Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of international research on androgen deprivation therapy (ADT) for prostate cancer ...

Men with prostate cancer who were treated with the GnRH agonist leuprolide had significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix.

New data presented at the American Urological Association (AUA) annual meeting further supported the use of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) for patients ...

If you’ve been diagnosed with advanced prostate cancer, there’s a good chance you’ll receive androgen deprivation therapy (ADT) at some point, as ADT is a mainstay of prostate cancer treatment. It ...

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

Adding Nubeqa to androgen deprivation therapy improved radiographic progression-free survival in patients with metastatic hormone-sensitive prostate cancer. The combination of Nubeqa (darolutamide) ...

Prostate cancer is the most common malignancy among men, with over 160,000 new cases diagnosed annually in the United States. Although advances in surgery, radiotherapy, and hormone therapy have ...

Recently, the research group led by Dr. Dechao Feng, Lecturer at University College London (UCL) and Distinguished Research ...

Nonlinear improvement seen in relative benefit of distant metastasis, OS, with reduced benefits beyond 9 to 12 months of ADT. HealthDay News — Increasing duration of androgen deprivation therapy (ADT) ...

In men with hormone-sensitive metachronous oligometastatic prostate cancer, the use of stereotactic body radiotherapy (SBRT) commonly delayed the need for long-term ADT and provided durable disease ...

U.S. study supports findings from a global trial using an external control arm ...